{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:25:16Z","timestamp":1787217916051,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.ajkd.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:47:07Z","timestamp":1781624827000},"page":"366-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes"],"prefix":"10.1053","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7402","authenticated-orcid":false,"given":"Joshua J.","family":"Neumiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sindhu","family":"Swarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy M.","family":"Mickelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Dryden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1053\/j.ajkd.2026.04.007_bib1","first-page":"S1","article-title":"Standards of care in diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"3 suppl 1","key":"10.1053\/j.ajkd.2026.04.007_bib3","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2022.12.001","article-title":"US Renal Data System 2022 annual data report: epidemiology of kidney disease in the United States","volume":"81","author":"Johansen","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"10105","key":"10.1053\/j.ajkd.2026.04.007_bib4","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"9854","key":"10.1053\/j.ajkd.2026.04.007_bib6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ajkd.2026.04.007_bib7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"De Boer","year":"2022","journal-title":"Kidney Int"},{"issue":"5 suppl","key":"10.1053\/j.ajkd.2026.04.007_bib8","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2026.04.007_bib9","first-page":"S239","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes care"},{"issue":"24","key":"10.1053\/j.ajkd.2026.04.007_bib10","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.ajkd.2026.04.007_bib11","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2026.04.007_bib14","first-page":"S181","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2215\/CJN.0000000587","article-title":"Kidney outcomes with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas in type 2 diabetes and moderate cardiovascular risk","volume":"20","author":"Neumiller","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2026.04.007_bib16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s11606-017-4061-7","article-title":"Shifting paradigms in the medical management of type 2 diabetes: reflections on recent cardiovascular outcome trials","volume":"32","author":"Ismail-Beigi","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1053\/j.ajkd.2026.04.007_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s44161-024-00453-9","article-title":"Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk","volume":"3","author":"McCoy","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"10.1053\/j.ajkd.2026.04.007_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112910","article-title":"Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial","volume":"229","author":"Sklepinski","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2215\/CJN.0000000584","article-title":"The impact of glucagon-like peptide-1 receptor agonists on kidney outcomes: a meta-analysis of randomized placebo-controlled trials","volume":"20","author":"Mendonca","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.04.007_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1053\/j.ajkd.2026.04.007_bib21","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pcd.2020.08.017","article-title":"Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials","volume":"15","author":"Wei","year":"2021","journal-title":"Prim Care Diabetes"},{"issue":"8","key":"10.1053\/j.ajkd.2026.04.007_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.04.007_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100852","article-title":"Derivation of an annualized claims-based major adverse cardiovascular event estimator in type 2 diabetes","volume":"3","author":"McCoy","year":"2024","journal-title":"JACC Adv"},{"issue":"8","key":"10.1053\/j.ajkd.2026.04.007_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1053\/j.ajkd.2026.04.007_bib26","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1053\/j.ajkd.2026.04.007_bib27","article-title":"SuperLearner: Super Learner Prediction","volume":"2.0-28","author":"Polley","year":"2023","journal-title":"R package version"},{"issue":"19","key":"10.1053\/j.ajkd.2026.04.007_bib28","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"10.1053\/j.ajkd.2026.04.007_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner","volume":"6","author":"Van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"8","key":"10.1053\/j.ajkd.2026.04.007_bib30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/sim.10003","article-title":"Targeted learning in observational studies with multi-valued treatments: an evaluation of antipsychotic drug treatment safety","volume":"43","author":"Poulos","year":"2024","journal-title":"Stat Med"},{"key":"10.1053\/j.ajkd.2026.04.007_bib31","unstructured":"Greifer N SE. Choosing the causal estimand for propensity score analysis of observational studies. Methodology (stat.ME). arXiv. 2106.10577. doi:10.48550\/arXiv.2106.10577."},{"issue":"3","key":"10.1053\/j.ajkd.2026.04.007_bib32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.ackd.2018.01.008","article-title":"Competing risk of death with end-stage renal disease in diabetic kidney disease","volume":"25","author":"Jiang","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2026.04.007_bib34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"10.1053\/j.ajkd.2026.04.007_bib35","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"10.1053\/j.ajkd.2026.04.007_bib36","series-title":"Design and Analysis of Clinical Trials with Time-to-Event Endpoints","first-page":"455","article-title":"Application of time-to-event methods in the assessment of safety in clinical trials","author":"Moore","year":"2009"},{"issue":"3","key":"10.1053\/j.ajkd.2026.04.007_bib37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"17","key":"10.1053\/j.ajkd.2026.04.007_bib38","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/sim.7297","article-title":"Causal inference in survival analysis using pseudo-observations","volume":"36","author":"Andersen","year":"2017","journal-title":"Stat Med"},{"issue":"10","key":"10.1053\/j.ajkd.2026.04.007_bib39","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/sim.9681","article-title":"A comparison of different methods to adjust survival curves for confounders","volume":"42","author":"Denz","year":"2023","journal-title":"Stat Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib40","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1214\/20-EJS1740","article-title":"Correcting an estimator of a multivariate monotone function with isotonic regression","volume":"14","author":"Westling","year":"2020","journal-title":"Electron J Stat"},{"key":"10.1053\/j.ajkd.2026.04.007_bib41","article-title":"Sensitivity analysis via the proportion of unmeasured confounding","author":"Bonvini","year":"1912","journal-title":"Methodology (stat.ME)"},{"issue":"1","key":"10.1053\/j.ajkd.2026.04.007_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.0006-341X.2001.00103.x","article-title":"Methods for conducting sensitivity analysis of trials with potentially nonignorable competing causes of censoring","volume":"57","author":"Rotnitzky","year":"2001","journal-title":"Biometrics"},{"issue":"3","key":"10.1053\/j.ajkd.2026.04.007_bib43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"Prasad","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2026.04.007_bib44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"4","key":"10.1053\/j.ajkd.2026.04.007_bib45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.ajkd.2026.04.007_bib46","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1053\/j.ajkd.2026.04.007_bib47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"20","key":"10.1053\/j.ajkd.2026.04.007_bib48","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2026.04.007_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.04.007_bib50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1053\/j.ajkd.2026.04.007_bib51","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1053\/j.ajkd.2026.04.007_bib52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2337\/dci24-0091","article-title":"Compounded GLP-1 and dual GIP\/GLP-1 receptor agonists: a statement from the American Diabetes Association","volume":"48","author":"Neumiller","year":"2025","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1053\/j.ajkd.2026.04.007_bib54","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/aje\/kwm165","article-title":"The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study","volume":"166","author":"Fewell","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.04.007_bib55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/pds.5398","article-title":"Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data","volume":"31","author":"Paik","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1053\/j.ajkd.2026.04.007_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12882-024-03478-1","article-title":"The ICD-9 to ICD-10 transition has not improved identification of rapidly progressing stage 3 and stage 4 chronic kidney disease patients: a diagnostic test study","volume":"25","author":"Jalal","year":"2024","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib57","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1053\/j.ajkd.2025.03.021","article-title":"Validation of an algorithm to identify end-stage kidney disease in electronic health records data","volume":"86","author":"Gao","year":"2025","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2026.04.007_bib58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.ajkd.2015.01.016","article-title":"Kidney failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) Study: comparing ascertainment of treated and untreated kidney failure in a cohort study","volume":"66","author":"Rebholz","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2026.04.007_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626009649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626009649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:42:39Z","timestamp":1787215359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626009649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0272638626009649"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.04.007","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}